source
- Amylyx reports avexitide cuts severe hypoglycemia by 55% in bariatric surgery patientsAmylyx Pharmaceuticals announced that its GLP-1 blocker avexitide achieved the primary endpoint in a late‑stage trial, reducing serious to severe hypoglycemic events by 55% compared with placebo in…
- CSL Vifor warns Tavneos exit from Europe will cut revenue by about 25%CSL Vifor’s parent company CSL Limited said the withdrawal of the drug Tavneos from the European market creates a significant headwind for sales. The company expects its revenue to fall by roughly…